Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exclusivity Period For NDIs Would Promote R&D, Consultants Claim

This article was originally published in The Tan Sheet

Executive Summary

A term of exclusivity for novel dietary supplement products would spur R&D investment by manufacturers, according to George Burdock, PhD, president of the Burdock Group

You may also be interested in...



Supplement GMPs, NDI Guidance Should Top CFSAN 2007 Priority List – CRN

The Council for Responsible Nutrition urges FDA's Center for Food Safety & Applied Nutrition to make the publication of the good manufacturing practices for dietary supplements final rule a prominent program priority for 2007

Supplement GMPs, NDI Guidance Should Top CFSAN 2007 Priority List – CRN

The Council for Responsible Nutrition urges FDA's Center for Food Safety & Applied Nutrition to make the publication of the good manufacturing practices for dietary supplements final rule a prominent program priority for 2007

Supplement GMPs, NDI Guidance Should Top CFSAN 2007 Priority List – CRN

The Council for Responsible Nutrition urges FDA's Center for Food Safety & Applied Nutrition to make the publication of the good manufacturing practices for dietary supplements final rule a prominent program priority for 2007

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS097536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel